{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:59:38Z","timestamp":1770418778507,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40257-020-00575-3","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T07:02:39Z","timestamp":1606374159000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-4725","authenticated-orcid":false,"given":"Tasnim","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-660X","authenticated-orcid":false,"given":"Mark","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-7144","authenticated-orcid":false,"given":"Dorra","family":"Bouazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-478X","authenticated-orcid":false,"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-2540","authenticated-orcid":false,"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"issue":"1","key":"575_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41702-019-0052-0","volume":"4","author":"K Phan","year":"2020","unstructured":"Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation\u2014systematic review and meta-analysis. Biomed Dermatol. 2020;4(1):2. https:\/\/doi.org\/10.1186\/s41702-019-0052-0.","journal-title":"Biomed Dermatol."},{"issue":"5","key":"575_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000507323","volume":"236","author":"LAV Orenstein","year":"2020","unstructured":"Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;236(5):393\u2013412.","journal-title":"Dermatology"},{"key":"575_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16023","author":"HH van der Zee","year":"2019","unstructured":"van der Zee HH, Longcore M, Geng Z, et al. Weekly adalimumab treatment decreased disease flare in Hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2019. https:\/\/doi.org\/10.1111\/jdv.16023.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"12","key":"575_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846\u201355.","journal-title":"Ann Intern Med."},{"issue":"5","key":"575_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"575_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"575_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434\u201342.","journal-title":"Br J Dermatol."},{"issue":"1","key":"575_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-69.e2.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"575_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/bjd.17919","volume":"181","author":"GBE Jemec","year":"2019","unstructured":"Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181(5):967\u201375.","journal-title":"Br J Dermatol"},{"issue":"4 Suppl 1","key":"575_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2011.11.230","volume":"66","author":"C Zouboulis","year":"2012","unstructured":"Zouboulis C, Adams D, Chen K, et al. Impact of weight and body mass index on high-sensitivity C-reactive protein response to adalimumab in hidradenitis suppurativa patients. J Am Acad Dermatol. 2012;66(4 Suppl 1):53. https:\/\/doi.org\/10.1016\/j.jaad.2011.11.230.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"575_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjd.12192","volume":"168","author":"GBE Jemec","year":"2013","unstructured":"Jemec GBE. Predicting response to anti-TNF-alpha treatment in Hidradenitis suppurativa. Br J Dermatol. 2013;168(2):233.","journal-title":"Br J Dermatol."},{"issue":"12","key":"575_CR12","doi-asserted-by":"publisher","first-page":"e011941","DOI":"10.1136\/bmjopen-2016-011941","volume":"6","author":"G Lombardi","year":"2016","unstructured":"Lombardi G, Perego S, Sansoni V, et al. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open. 2016;6(12):e011941.","journal-title":"BMJ Open."},{"issue":"7","key":"575_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"575_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","volume":"83","author":"A Hoxha","year":"2016","unstructured":"Hoxha A, Calligaro A, Tonello M, et al. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Jt Bone Spine. 2016;83(2):167\u201371.","journal-title":"Jt Bone Spine."},{"issue":"6","key":"575_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","volume":"113","author":"B Ungar","year":"2018","unstructured":"Ungar B, Engel T, Yablecovitch D, et al. Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study. Am J Gastroenterol. 2018;113(6):890\u20138.","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"575_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/apt.14318","volume":"46","author":"H Nakase","year":"2017","unstructured":"Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn\u2019s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017;46(9):873\u201382.","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"575_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","volume":"56","author":"A Nader","year":"2017","unstructured":"Nader A, Beck D, Noertersheuser P, et al. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56(9):1091\u2013102.","journal-title":"Clin Pharmacokinet."},{"key":"575_CR18","unstructured":"Maisonneuve-Rosemont Hospital Research Centre (CRHMR). D\u00e9tection de l\u2019adalimumab et des anticorps anti-adalimumab par ELISA [Detection of adalimumab and anti-adalimumab antibodies by ELISA]. Quebec, Canada. L\u2019Institut national d\u2019excellence en sant\u00e9 et en services sociaux (The National Institute of Excellence in Health and Social Services); 2017. 28 p. Report 2015.04.01R. https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Analyse_biomedicale\/Octobre_2017\/02-INESSS_Detection_adalimumab_anticorps_anti-adalimumab_elisa.pdf. Accessed 19 Oct 2019."},{"key":"575_CR19","unstructured":"Dynacare Blood Test Labs & Health Services. ADALIMUMAB [Internet]. Dynacare. https:\/\/www.dynacare.ca\/specialpages\/secondarynav\/find-a-test\/nat\/adalimumab.aspx?sa=a&. Accessed 27 Oct 2019."},{"issue":"3","key":"575_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827\u201334.","journal-title":"Gastroenterology"},{"issue":"1","key":"575_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.15233","volume":"33","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization\u2014systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19\u201331.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"8","key":"575_CR22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559\u201382.","journal-title":"J Rheumatol."},{"key":"575_CR23","first-page":"1","volume":"18","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Hansen H, Caposiena Caro RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa. DRM. 2019;18:1\u20136.","journal-title":"DRM."},{"issue":"5","key":"575_CR24","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","volume":"137","author":"K Karmiris","year":"2009","unstructured":"Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease. Gastroenterology. 2009;137(5):1628\u201340.","journal-title":"Gastroenterology"},{"issue":"8","key":"575_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","volume":"13","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019;13(8):976\u201381.","journal-title":"J Crohns Colitis."},{"issue":"14","key":"575_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460\u20138.","journal-title":"JAMA"},{"issue":"5","key":"575_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ecco-jcc\/jjw014","volume":"10","author":"E Zittan","year":"2016","unstructured":"Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn\u2019s disease. J Crohns Colitis. 2016;10(5):510\u20135.","journal-title":"J Crohns Colitis."},{"issue":"7","key":"575_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320-1329.e3.","journal-title":"Gastroenterology"},{"issue":"6","key":"575_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","volume":"40","author":"Y Mazor","year":"2014","unstructured":"Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;40(6):620\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"575_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","volume":"46","author":"N Mitrev","year":"2017","unstructured":"Mitrev N, Casteele NV, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11\u201312):1037\u201353.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"575_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","volume":"11","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243\u201355.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"8","key":"575_CR32","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1097\/MIB.0000000000000772","volume":"22","author":"C Steenholdt","year":"2016","unstructured":"Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999\u20132015.","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"575_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","volume":"11","author":"S Ben-Horin","year":"2013","unstructured":"Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444\u20137.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"575_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apt.13862","volume":"45","author":"B Ungar","year":"2017","unstructured":"Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45(2):276\u201382.","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"575_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","volume":"148","author":"B Bressler","year":"2015","unstructured":"Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035-1058.e3.","journal-title":"Gastroenterology"},{"issue":"12","key":"575_CR36","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947\u201355.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"575_CR37","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","volume":"58","author":"MJH Doeleman","year":"2019","unstructured":"Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(10):1839\u201349.","journal-title":"Rheumatology (Oxford)"},{"key":"575_CR38","doi-asserted-by":"crossref","unstructured":"Ducourau E, Rispens T, Samain M, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6(1). https:\/\/rmdopen.bmj.com\/content\/6\/1\/e001047. Accessed 26 Feb 2020.","DOI":"10.1136\/rmdopen-2019-001047"},{"issue":"1","key":"575_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3899\/jrheum.140685","volume":"42","author":"M Zisapel","year":"2015","unstructured":"Zisapel M, Zisman D, Madar-Balakirski N, et al. Prevalence of TNF-\u03b1 blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015;42(1):73\u20138.","journal-title":"J Rheumatol."},{"issue":"5","key":"575_CR40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","volume":"180","author":"JR Ingram","year":"2019","unstructured":"Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009\u201317.","journal-title":"Br J Dermatol"},{"issue":"2","key":"575_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jaad.2019.09.012","volume":"82","author":"LL Wang","year":"2020","unstructured":"Wang LL, Micheletti RG. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review. J Am Acad Dermatol. 2020;82(2):507\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"575_CR42","first-page":"1","volume":"1","author":"KT Savage","year":"2019","unstructured":"Savage KT, Flood KS, Porter ML, et al. TNF-\u03b1 inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;1(10):1\u201312.","journal-title":"Ther Adv Chronic Dis."},{"issue":"3","key":"575_CR43","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/1203475418823529","volume":"23","author":"ML McPhie","year":"2019","unstructured":"McPhie ML, Bridgman AC, Kirchhof MG. Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients. J Cutan Med Surg. 2019;23(3):270\u20136.","journal-title":"J Cutan Med Surg."},{"issue":"5","key":"575_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341\u201353.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"575_CR45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","volume":"26","author":"S Atiqi","year":"2020","unstructured":"Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;26(11):312.","journal-title":"Front Immunol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00575-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00575-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00575-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T06:18:33Z","timestamp":1616048313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00575-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00575-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article. Similar to routine practice in gastroenterology, the cost of performing TDM (measuring AAA and drug levels through Life Labs) was covered by AbbVie, the producers of adalimumab. AbbVie played no role in the data collection, analysis, interpretation, writing, or final approval of the manuscript nor the decision to submit the manuscript for publication. The costs for the submission to\/approval by Independent Research Review Board Inc were covered by the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TA, MM, and DB have no conflicts of interest to disclose. AA has acted as a consultant and advisor for and\/or received research funding from AbbVie, Galderma, Janssen, LEO Pharma, Novartis, Sanofi Aventis, Valeant, Boehringer Ingelheim, DSBiopharma, Eli Lilly, Glenmark, Incyte, Ilkos, Merck Serono, Pfizer, Regeneron, Roche, Xenon, and Xoma. MAL has served on the advisory boards for AbbVie and Janssen and consulted for Almirall, BSN, Incyte, Kymera, and Xbiotech. GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Novartis, Pierre Fabre, and UCB for participation on advisory boards; has received grants from AbbVie, AstraZeneca, Inflarx, Janssen-Cilag, Leo Pharma, Novartis, Regeneron, and Sanofi for participation as an investigator; has received speaker honoraria from AbbVie, Boehringer Ingelheim, Galderma, and MSD; and has received unrestricted departmental grants from AbbVie, Leo Pharma, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study was approved by the Canadian Independent Research Review Board Inc (ID: 2018.511).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (retrospective study).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Individuals have given consent to have their data published.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. AA conceived the idea for the article. AA, DB, and MM performed data collection. TA performed the data analysis. The first draft of the manuscript was written by TA, and all authors contributed to writing, reviewing, and critically revising previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}